XML 73 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:      
Revenues $ 176,232,000 $ 111,299,000 $ 110,701,000
Operating expenses:      
Research and development 234,057,000 249,898,000 230,819,000
General and administrative 61,167,000 62,682,000 63,219,000
Impairment of goodwill and indefinite-lived intangible assets 89,485,000 0 0
Impairment of long-lived assets 65,528,000 0 0
Total operating expenses 450,237,000 312,580,000 294,038,000
Loss from operations (274,005,000) (201,281,000) (183,337,000)
Interest and other income, net 11,102,000 9,432,000 5,346,000
Loss before income taxes (262,903,000) (191,849,000) (177,991,000)
Income tax (benefit) expense (5,072,000) 429,000 306,000
Net loss (257,831,000) (192,278,000) (178,297,000)
Net loss attributable to non-controlling interest 0 0 (11,000)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders $ (257,831,000) $ (192,278,000) $ (178,286,000)
Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share) $ (1.48) $ (1.25) $ (1.23)
Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share) $ (1.48) $ (1.25) $ (1.23)
Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 174,444 154,345 144,568
Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 174,444 154,345 144,568